Italia markets closed

Alpha Tau Medical Ltd. (DRTS)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
2,4900+0,1200 (+5,06%)
Alla chiusura: 04:00PM EDT
2,5800 +0,09 (+3,61%)
Dopo ore: 05:16PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente2,3700
Aperto2,4300
Denaro2,4000 x 100
Lettera2,5300 x 100
Min-Max giorno2,3900 - 2,4900
Intervallo di 52 settimane2,1500 - 4,8000
Volume45.860
Media Volume34.636
Capitalizzazione173,48M
Beta (5 anni mensile)0,71
Rapporto PE (ttm)N/D
EPS (ttm)-0,4200
Prossima data utiliN/D
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A9,25
  • GlobeNewswire

    Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now

    MIAMI, Oct. 03, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 63rd Emerging Growth Conference on October 4th and 5th, 2023. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the conference here. Submit Questions for any of the presenting

  • GlobeNewswire

    Alpha Tau Treats First Patient with Advanced Inoperable Pancreatic Cancer at Israel’s Hadassah Medical Center

    JERUSALEM, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that a patient with advanced inoperable pancreatic cancer has been treated in a clinical trial at Hadassah Medical Center in Jerusalem, Israel. The trial is designed for a broad range of solid tumor patients who do not qualify for participation in other existing trials or who do not

  • GlobeNewswire

    Alpha Tau Medical Announces Second Quarter 2023 Financial Results and Provides Corporate Update

    – Treated the first patient with advanced inoperable pancreatic cancer in a safety and feasibility trial in Canada in April – – 89% CR, two-year local recurrence-free survival of 77%, and no treatment-related grade 2 or higher late-onset toxicity reported from an analysis of four feasibility trials in 71 patients with unresectable skin and head and neck cancers – – Valuable land grant received in Jerusalem to enable a standalone company headquarters and future increased manufacturing capacity –